As it heads into the upfronts, the tech giant is leaning on the NFL, NBA, WNBA and other events to drive its ad business ...

The co-antibody therapy JNJ-4804 -- a fixed-dose combination of guselkumab (Tremfya) and golimumab (Simponi) -- showed clinically meaningful efficacy exceeding that of either drug alone in patients ...

SoFi Stadium is the site of Super Bowl LXI, and both teams have aspirations of playing in that game. The Chiefs; last meeting ...

Discusses BGE-102 Clinical Results and Development Strategy for Cardiovascular and Retinal Disease May 8, 2026 12:30 PM ...

Held at The Warehouse, a venue Fimmel says provides a “particularly awesome experience” for live music, FimFest is an ...

A comparative analysis identifies the top IL-23 inhibitors that were least likely to be associated with the development of ...

One-year results: About 25% of patients achieved remission and 31% showed clinical response at 52 weeks on upadacitinib. Study design: Retrospective analysis of 59 patients across 13 French centers, ...

If you’re one of the estimated 10 million people in the UK living with the agony of osteoarthritis (OA), chances are you’ve ...

Upadacitinib is effective in inducing clinical response and remission and is generally well tolerated in patients with ...

New study suggests alterations in gut microbiota, gene expression and metabolism, with some effects persisting in offspring A new study from the University of Chile suggests that common artificial ...

Bristol Myers Squibb today announced that the European Commission has granted approval to Sotyktu (deucravacitinib), alone or in combination with methotrexate, for the treatment of active psoriatic ...